{"id":"NCT04759131","sponsor":"Bioverativ, a Sanofi company","briefTitle":"Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A","officialTitle":"A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-19","primaryCompletion":"2023-01-18","completion":"2023-01-18","firstPosted":"2021-02-18","resultsPosted":"2024-02-13","lastUpdate":"2025-09-11"},"enrollment":74,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"DRUG","name":"efanesoctocog alfa (BIVV001)","otherNames":[]}],"arms":[{"label":"BIVV001: Participants aged <6 Years","type":"EXPERIMENTAL"},{"label":"BIVV001: Participants aged 6 to <12 Years","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\n\\- To evaluate the safety of BIVV001 in previously treated pediatric participants with hemophilia A.\n\nSecondary Objectives:\n\n* To evaluate the efficacy of BIVV001 as a prophylaxis treatment.\n* To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes.\n* To evaluate BIVV001 consumption for prevention and treatment of bleeding episodes.\n* To evaluate the effect of BIVV001 prophylaxis on joint health outcomes.\n* To evaluate the effect of BIVV001 prophylaxis on Quality of Life (QoL) outcomes.\n* To evaluate the efficacy of BIVV001 for perioperative management.\n* To evaluate the safety and tolerability of BIVV001 treatment.\n* To assess the pharmacokinetics (PK) of BIVV001.","primaryOutcome":{"measure":"Number of Participants With Neutralising Antibodies (Development of Inhibitors) Directed Against Factor VIII","timeFrame":"Baseline up to Week 52","effectByArm":[{"arm":"BIVV001: Participants Aged <6 Years","deltaMin":0,"sd":null},{"arm":"BIVV001: Participants Aged 6 to <12 Years","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":40,"countries":["United States","Australia","Canada","France","Germany","Hungary","Ireland","Italy","Netherlands","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["40701256","40099428","39018533"],"seeAlso":["https://www.trialsummaries.com/Study/StudyDetails?id=25243&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":38},"commonTop":["Upper Respiratory Tract Infection","Sars-Cov-2 Test Positive","Pyrexia","Asymptomatic Covid-19","Gastroenteritis Viral"]}}